Rocket Pharmaceuticals (RCKT) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Document Transition Report	false
Entity File Number	001-36829
Entity Registrant Name	Rocket Pharmaceuticals, Inc.
Entity Central Index Key	0001281895
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3475813
Entity Address, Address Line One	9 Cedarbrook Drive
Entity Address, City or Town	Cranbury
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08512
City Area Code	609
Local Phone Number	659-8001
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	RCKT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		80,525,531

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,076	$ 140,517
Investments	261,964	215,877
Prepaid expenses and other current assets	5,034	7,666
Total current assets	312,074	364,060
Property and equipment, net	32,986	29,009
Goodwill	39,154	39,154
Intangible assets	25,724	25,724
Restricted cash	1,362	1,340
Deposits	542	608
Investments	0	43,276
Operating lease right-of-use assets	4,345	1,972
Finance lease right-of-use asset	45,594	46,664
Total assets	461,781	551,807
Current liabilities:
Accounts payable and accrued expenses	31,353	36,660
Operating lease liabilities, current	1,233	773
Finance lease liability, current	1,760	1,736
Total current liabilities	34,346	39,169
Operating lease liabilities, non-current	3,074	1,088
Finance lease liability, non-current	19,319	19,269
Other liabilities	2,072	2,595
Total liabilities	58,811	62,121
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.01 par value, 120,000,000 shares authorized; 80,521,415 and 79,123,312 shares issued and 80,518,844 and 79,120,741 shares outstanding at June 30, 2023 and December 31, 2022, respectively	805	791
Treasury stock, at cost, 2,571 common shares at June 30, 2023 and December 31, 2022	(47)	(47)
Additional paid-in capital	1,240,745	1,203,074
Accumulated other comprehensive loss	(722)	(357)
Accumulated deficit	(837,811)	(713,775)
Total stockholders' equity	402,970	489,686
Total liabilities and stockholders' equity	461,781	551,807
Series A Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock	0	0
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	80,521,415	79,123,312
Common stock, shares outstanding (in shares)	80,518,844	79,120,741
Treasury stock, at cost (in shares)	2,571	2,571
Series A Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	51,383	41,356	97,754	72,150
General and administrative	17,374	12,854	33,197	24,624
Total operating expenses	68,757	54,210	130,951	96,774
Loss from operations	(68,757)	(54,210)	(130,951)	(96,774)
Interest expense	(468)	(465)	(936)	(928)
Interest and other income, net	846	669	2,754	1,291
Accretion of discount and amortization of premium on investments, net	2,678	(396)	5,097	(973)
Net loss	$ (65,701)	$ (54,402)	$ (124,036)	$ (97,384)
Net loss per share - basic (in dollars per share)	$ (0.82)	$ (0.83)	$ (1.55)	$ (1.5)
Net loss per share - diluted (in dollars per share)	$ (0.82)	$ (0.83)	$ (1.55)	$ (1.5)
Weighted-average common shares outstanding - basic (in shares)	80,472,362	65,476,531	79,965,755	64,995,797
Weighted-average common shares outstanding - diluted (in shares)	80,472,362	65,476,531	79,965,755	64,995,797

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (65,701)	$ (54,402)	$ (124,036)	$ (97,384)
Other comprehensive loss
Net unrealized loss on investments	(639)	(136)	(367)	(604)
Total comprehensive loss	$ (66,340)	$ (54,538)	$ (124,403)	$ (97,988)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2021	$ 645	$ 0	$ 946,152	$ (161)	$ (491,912)	$ 454,724
Beginning Balance (in shares) at Dec. 31, 2021	64,505,889
Issuance of common stock pursuant to exercise of stock options and restricted stock units	$ 0	0	76	0	0	76
Issuance of common stock pursuant to exercise of stock options and restricted stock units (in shares)	16,168
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	(468)	0	(468)
Stock-based compensation	0	0	6,270	0	0	6,270
Net loss	0	0	0	0	(42,982)	(42,982)
Ending Balance at Mar. 31, 2022	$ 645	0	952,498	(629)	(534,894)	417,620
Ending Balance (in shares) at Mar. 31, 2022	64,522,057
Beginning Balance at Dec. 31, 2021	$ 645	0	946,152	(161)	(491,912)	454,724
Beginning Balance (in shares) at Dec. 31, 2021	64,505,889
Net loss						(97,384)
Ending Balance at Jun. 30, 2022	$ 658	0	977,099	(765)	(589,296)	387,696
Ending Balance (in shares) at Jun. 30, 2022	65,837,894
Beginning Balance at Mar. 31, 2022	$ 645	0	952,498	(629)	(534,894)	417,620
Beginning Balance (in shares) at Mar. 31, 2022	64,522,057
Issuance of common stock pursuant to exercise of stock options	$ 0	0	3	0	0	3
Issuance of common stock pursuant to exercise of stock options (in shares)	2,387
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs	$ 13	0	17,229	0	0	17,242
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)	1,313,450
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	(136)	0	(136)
Stock-based compensation	0	0	7,369	0	0	7,369
Net loss	0	0	0	0	(54,402)	(54,402)
Ending Balance at Jun. 30, 2022	$ 658	0	977,099	(765)	(589,296)	387,696
Ending Balance (in shares) at Jun. 30, 2022	65,837,894
Beginning Balance at Dec. 31, 2022	$ 791	(47)	1,203,074	(357)	(713,775)	489,686
Beginning Balance (in shares) at Dec. 31, 2022	79,123,312
Issuance of common stock pursuant to exercise of stock options	$ 1	0	1,113	0	0	1,114
Issuance of common stock pursuant to exercise of stock options (in shares)	88,429
Issuance of common stock pursuant to vesting of restricted stock units	$ 1	0	(1)	0	0	0
Issuance of common stock pursuant to vesting of restricted stock units (in shares)	126,060
Issuance of common stock pursuant to exercise of warrants	$ 1	0	6	0	0	7
Issuance of common stock pursuant to exercise of warrant (in shares)	126,093
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs	$ 10	0	17,212	0	0	17,222
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)	948,300
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	267	0	267
Stock-based compensation	0	0	8,915	0	0	8,915
Net loss	0	0	0	0	(58,335)	(58,335)
Ending Balance at Mar. 31, 2023	$ 804	(47)	1,230,319	(90)	(772,110)	458,876
Ending Balance (in shares) at Mar. 31, 2023	80,412,194
Beginning Balance at Dec. 31, 2022	$ 791	(47)	1,203,074	(357)	(713,775)	489,686
Beginning Balance (in shares) at Dec. 31, 2022	79,123,312
Net loss						(124,036)
Ending Balance at Jun. 30, 2023	$ 805	(47)	1,240,745	(722)	(837,811)	402,970
Ending Balance (in shares) at Jun. 30, 2023	80,521,415
Beginning Balance at Mar. 31, 2023	$ 804	(47)	1,230,319	(90)	(772,110)	458,876
Beginning Balance (in shares) at Mar. 31, 2023	80,412,194
Issuance of common stock pursuant to exercise of stock options	$ 0	0	182	0	0	182
Issuance of common stock pursuant to exercise of stock options (in shares)	48,088
Issuance of common stock pursuant to vesting of restricted stock units	$ 1	0	(1)	0	0	0
Issuance of common stock pursuant to vesting of restricted stock units (in shares)	61,133
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	(632)	0	(632)
Stock-based compensation	0	0	10,245	0	0	10,245
Net loss	0	0	0	0	(65,701)	(65,701)
Ending Balance at Jun. 30, 2023	$ 805	$ (47)	$ 1,240,745	$ (722)	$ (837,811)	$ 402,970
Ending Balance (in shares) at Jun. 30, 2023	80,521,415

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (124,036)	$ (97,384)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	2,327	1,798
Amortization of finance lease right of use asset	1,077	1,070
Write down of property and equipment, net	0	177
Stock-based compensation	19,160	13,639
Amortization of premium and accretion of discount on investments, net	(4,831)	977
Changes in operating assets and liabilities:
Prepaid expenses and other assets	2,698	(1,084)
Accounts payable and accrued expenses	(4,477)	2,548
Operating lease liabilities	102	(64)
Finance lease liability	74	90
Other liabilities	(523)	(29)
Net cash used in operating activities	(108,429)	(78,262)
Investing activities:
Purchases of investments	(168,930)	(143,023)
Proceeds from maturities of investments	170,585	163,669
Payments made to acquire right of use asset	(36)	0
Purchases of property and equipment	(7,134)	(4,852)
Net cash (used in) provided by investing activities	(5,515)	15,794
Financing activities:
Issuance of common stock, pursuant to exercise of stock options	1,296	79
Exercise of warrants	7	0
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs	17,222	17,243
Net cash provided by financing activities	18,525	17,322
Net change in cash, cash equivalents and restricted cash	(95,419)	(45,146)
Cash, cash equivalents and restricted cash at beginning of period	141,857	234,037
Cash, cash equivalents and restricted cash at end of period	46,438	188,891
Supplemental disclosure of non-cash financing and investing activities:
Accrued purchases of property and equipment, ending balance	1,265	405
Unrealized loss on investments	$ (365)	$ (604)

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2023
Nature of Business [Abstract]
Nature of Business	1. Nature of Business Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) is a clinical-stage, multi-platform biotechnology company focused on the development of first, only and best in-class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. The Company has three clinical-stage ex vivo lentiviral vector (“LV”) programs. These include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency (“PKD”), a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. Of these, both the Phase 2 FA program and the Phase 1/2 LAD-I program produced data read outs in 2022 and regulatory filings in the United States (“U.S.”) and Europe (“EU”) are anticipated in 2023. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. In the U.S., the Company also has a clinical stage in vivo adeno-associated virus (“AAV”) program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Additionally, the Company has an AAV vector program targeting Plakophilin-2 Arrhythmogenic Cardiomyopathy (“PKP2-ACM”), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death. As a result of the Company’s acquisition of Renovacor Inc. (“Renovacor”) (see Note 14 “Renovacor Acquisition”), the Company is able to utilize recombinant AAV9-based gene therapy designed to slow or halt progression of BAG3 Dilated Cardiomyopathy (“DCM”), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. The Company has global commercialization and development rights to all of these product candidates under royalty-bearing license agreements.

Risks and Liquidity

Risks and Liquidity	6 Months Ended
	Jun. 30, 2023
Risks and Liquidity [Abstract]
Risks and Liquidity	2. Risks and Liquidity The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. The Company’s product candidates are in the development and clinical stage. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations and had an accumulated deficit of $837.8 million as of June 30, 2023. As of June 30, 2023, the Company had $307.0 million of cash, cash equivalents and investments. The Company expects such resources will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first half of 2025. On February 28, 2022, the Company entered into a sales agreement (the “Sales Agreement”), with Cowen and Company, LLC (“Cowen”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $200 million (the “Shares”) through Cowen as its sales agent. Through June 30, 2023, the Company has sold 4.2 million shares of common stock for net proceeds of $63.8 million pursuant to the at-the-market offering program (see Note 8 “Stockholders’ Equity”), including 0.9 million shares for net proceeds of $17.2 million during the six months ended June 30, 2023. In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.

Basis of Presentation, Principl

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]
Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies	3. Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (“2022 Form 10-K”). The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s consolidated financial position as of June 30, 2023 and the results of its operations and its cash flows for the three and six months June 30, 2023. The financial data and other information disclosed in these consolidated notes related to the three and six months June 30, 2023 and 2022 are unaudited. The results for the three and six months ended June 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 and any other interim periods or any future year or period. Significant Accounting Policies The significant accounting policies used in the preparation of these consolidated financial statements for the three and six months ended June 30, 2023 are consistent with those disclosed in Note 3 to the consolidated financial statements in the 2022 Form 10-K with most significant policies also being listed here. Principles of Consolidation The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany accounts have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of research and development (“R&D”) expenses, the valuation of equity transactions and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company’s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company’s operating leases (see Note 12 “Commitments and Contingencies” for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company’s corporate credit card. Cash, cash equivalents and restricted cash consist of the following: June 30, December 31, 2023 2022 Cash and cash equivalents $ 45,076 $ 140,517 Restricted cash 1,362 1,340 $ 46,438 $ 141,857 Concentrations of credit risk and off-balance sheet risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities consist of U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. The Company’s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. Investments Investments consist of U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company’s consolidated statement of operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). For the three and six months ended June 30, 2023 and 2022, there were no unrealized losses that were credit related. For the three and six months ended June 30, 2023, there were net unrealized losses on investments of $0.6 million and $0.4 million, respectively. For the three and six months ended June 30, 2022 there were net unrealized losses on investments of $0.1 million and $0.6 million, respectively. Intangible Assets Intangible assets related to in process research and development (“IPR&D”) projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&D intangible assets which are determined to have had a decrease in their fair value are adjusted downward and an expense is recognized in R&D expenses in the Consolidated Statements of Operations. These IPR&D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company’s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments. Warrants The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (”ASC 480”) and/or ASC Topic 815, Derivatives and Hedging (”ASC 815”), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company’s consolidated statement of operations. Stock-Based Compensation The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. That cost is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs and services are classified or in which the award recipient’s service payments are classified. Income Taxes In May 2022, the Company received a notice from the New York City Department of Finance regarding an audit of the NYC Biotechnology Credit for the tax periods ended December 31, 2018 through December 31, 2020, which was cleared as of June 30, 2023. Recent Accounting Pronouncements There were no recent accounting pronouncements that impacted the Company, or which had a significant effect on the consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments Items measured at fair value on a recurring basis are the Company’s investments. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of June 30, 2023 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market mutual funds $ 17,173 $ - $ - $ 17,173 Corporate Bonds - 3,480 - 3,480 United States Treasury securities 3,620 - - 3,620 20,793 3,480 - 24,273 Investments: Commercial Paper - 5,002 - 5,002 United States Treasury securities 188,971 - - 188,971 Corporate Bonds - 58,040 - 58,040 Agency Bonds - 9,951 - 9,951 188,971 72,993 - 261,964 Total assets $ 209,764 $ 76,473 $ - $ 286,237 Liabilities: Warrant liability $ - $ - $ 1,012 $ 1,012 Total liabilities $ - $ - $ 1,012 $ 1,012 Fair Value Measurements as of December 31, 2022 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market mutual funds $ 90,527 $ - $ - $ 90,527 Commercial Paper - 3,899 - 3,899 United States Treasury Securities 3,848 - - 3,848 Corporate Bonds - 8,618 - 8,618 94,375 12,517 - 106,892 Investments: Commercial Paper - 1,151 - 1,151 United States Treasury securities 189,444 - - 189,444 Corporate Bonds - 60,905 - 60,905 Agency Bonds - 7,653 - 7,653 189,444 69,709 - 259,153 Total assets $ 283,819 $ 82,226 $ - $ 366,045 Liabilities: Warrant liability $ - $ - $ 1,512 $ 1,512 Total liabilities $ - $ - $ 1,512 $ 1,512 The Company classifies its money market mutual funds and U.S. Treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its Commercial Paper and Corporate and Agency Bonds as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The reconciliation of the Company’s warrant liability, which is recorded as part of Other Liabilities in the consolidated balance sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrant Liability Balance, December 31, 2022 $ 1,512 Fair value adjustments (500 ) Balance, June 30, 2023 $ 1,012 The Company utilizes a Black-Scholes model to value the warrant liability (see Note 10 “Warrants”) at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the expected volatility of its common stock based on historical volatility of a peer group, considering the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the valuation date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero . The fair value of the warrant liability has been estimated with the following assumptions: June 30, 2023 December 31, 2022 Stock price $ 19.87 $ 18.39 Exercise price $ 65.23 $ 65.23 Expected volatility 67.91 % 71.25 % Risk-free interest rate 4.97 % 4.14 % Expected dividend yield - - Expected life (years) 1.82 2.39 Fair value per warrant $ 1.64 $ 2.45

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property and Equipment, Net [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net The Company’s property and equipment consisted of the following: June 30, December 31, 2023 2022 Laboratory equipment $ 24,723 $ 21,905 Machinery and equipment 11,714 11,326 Computer equipment 244 244 Furniture and fixtures 2,535 2,135 Leasehold improvements 3,289 589 Internal use software 1,903 1,903 44,408 38,102 Less: accumulated depreciation and amortization (11,422 ) (9,093 ) $ 32,986 $ 29,009 During the three and six months ended June 30, 2023 the Company recognized $1.2 million and $2.3 million of depreciation and amortization expense, respectively. During the three and six months ended June 30, 2022 the Company recognized $1.0 million and $1.8 million of depreciation and amortization expense, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2023
Intangible Assets and Goodwill [Abstract]
Intangible Assets and Goodwill	6. Intangible Assets and Goodwill The Company’s indefinite lived intangible assets consists of an acquired IPR&D asset and a mice colony model received from the acquisition of Renovacor. Intangible assets as of June 30, 2023 and December 31, 2022 are summarized as follows: Gross Carrying Value Accumulated Amortization Intangible Assets, Net In process research & development $ 25,150 $ - $ 25,150 Mice colony model 574 - 574 Total intangible assets $ 25,724 $ - $ 25,724 The gross carrying value of intangible assets was due to the acquisition of Renovacor (see Note 14 “Renovacor Acquisition”). The carrying value of Goodwill was $39.2 million as of June 30, 2023 and included $8.3 million as a result of the acquisition of Renovacor (see Note 14 “Renovacor Acquisition”).

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	7. Accounts Payable and Accrued Expenses As of June 30, 2023 and December 31, 2022, the Company’s accounts payable and accrued expenses consisted of the following: June 30 , December 31, 2023 2022 Research and development $ 20,329 $ 19,100 Employee compensation 6,013 10,006 Property and equipment 1,265 2,095 Professional fees 2,034 1,436 Acquisition related expenses - 1,153 Government grant payable 597 597 Other 1,115 2,273 $ 31,353 $ 36,660

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity At-the-Market Offering Program On February the Company entered into the Sales Agreement with Cowen with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares through Cowen as its sales agent. The shares to be offered and sold under the Sales Agreement, if any, will be offered and sold pursuant to the Company’s shelf registration statement on Form S- The Company filed a prospectus supplement with the SEC on February in connection with the offer and sale of the shares pursuant to the Sales Agreement. The Company will pay Cowen a cash commission of of gross proceeds from the sale of the shares pursuant to the Sales Agreement. The Company has provided Cowen with customary indemnification and contribution rights. The Company reimbursed Cowen for certain expenses incurred in connection with the Sales Agreement. Through June 30, 2023, the Company sold 4.2 million shares under the at-the-market offering program for gross proceeds of $65.8 million, less commissions of $2.0 million for net proceeds of $63.8 million. During the six months ended June 30, 2023, the Company sold 0.9 million shares under the at-the-market offering program for gross proceeds of $17.8 million, less commission of $0.6 million for net proceeds of $17.2 million.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation Stock Option Valuation The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of stock options granted to employees, non-employees and directors were as follows: Six June 30 2023 2022 Risk-free interest rate 3.96 % 2.32 % Expected term (in years) 5.84 5.79 Expected volatility 73.42 % 73.26 % Expected dividend yield - - Exercise price $ 20.20 $ 15.93 Fair value of common stock $ 20.20 $ 15.93 The following table summarizes stock option activity for the six months ended June 30, 2023: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding as of December 31, 2022 13,138,870 $ 14.52 5.46 $ 118,767 Granted 2,142,111 20.36 6.73 Exercised (136,517 ) 9.50 1,334 Cancelled or forfeited (269,314 ) 32.45 Outstanding as of June 30 2023 14,875,150 $ 15.08 5.67 $ 120,465 Options vested and exercisable as of June 30 2023 11,205,612 $ 12.91 4.51 $ 116,486 Options unvested as of June 30 2023 3,669,538 $ 21.71 9.23 $ 3,979 The weighted average grant-date fair value per share of stock options granted during the six months ended June 30, 2023 and 2022 was $13.46 and $10.32, respectively. The total fair value of options vested during the six months ended June 30, 2023 and 2022 was $19.9 million and $20.8 million, respectively. Restricted Stock Units (“RSU”) The following table summarizes the Company’s RSU activity for the six months ended June 30, 2023: Weighted Average Number of Grant Date Shares Fair Value Unvested as of December 31, 2022 992,874 $ 16.49 Granted 887,637 19.91 Vested (1) (187,297 ) 16.63 Forfeited (38,455 ) 18.33 Unvested as of June 30, 2023 1,654,759 $ 18.27 (1) Common stock issued is net of 104 shares related to taxes. Stock-Based Compensation Expense Stock-based compensation expense recognized by award type was as follows: Three Months Ended June 30, Six June 30 2023 2022 2023 2022 Stock options $ 7,455 $ 6,677 $ 14,440 $ 12,638 Restricted stock units 2,790 692 4,720 1,001 Total stock-based compensation expense $ 10,245 $ 7,369 $ 19,160 $ 13,639 Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 4,638 $ 2,889 $ 8,457 $ 5,207 General and administrative 5,607 4,480 10,703 8,432 Total stock-based compensation expense $ 10,245 $ 7,369 $ 19,160 $ 13,639 As of June 30, 2023, the Company had an aggregate of $70.5 million of unrecognized stock-based compensation expense related to both stock options and RSU grants, which is expected to be recognized over the weighted average period of 1.45 years.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2023
Warrants [Abstract]
Warrants	10 . Warrants A summary of the warrants outstanding as of June 30, 2023 is as follows: Exercise Price Outstanding Grant/Assumption Date Expiration Date 57.11 603,386 December 21, 2020 December 21, 2030 33.63 301,291 August 9, 2021 August 9, 2031 22.51 153,155 December 17, 2021 December 17, 2031 22.51 153,155 December 17, 2021 December 17, 2031 65.23 617,050 December 1, 2022 April 23, 2025 65.23 760,086 December 1, 2022 December 1, 2026 Total 2,588,123 The following table below is a summary of changes in warrants to purchase common stock for the six months ended June 30, 2023: Number of Warrant Shares Outstanding and Exercise Price Exercisable per Share Balance as of December 31, 2022 2,721,267 Granted - $ - Exercised (126,093 ) 0.06 Expired (7,051 ) $ 24.42 Balance as of June 30, 2023 2,588,123 Assumed Renovacor Public Warrants In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-acquisition public warrants (“Public Warrants”) that were converted into Rocket warrants with a right to purchase 760,086 of Rocket common shares at an exercise price of $65.23 per share. The Company determined that the Public Warrants met all of the criteria for equity classification. Accordingly, upon closing of the Merger, the Public Warrants were recorded as a component of additional paid-in capital of $3.4 million. Assumed Renovacor Private Warrants In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-acquisition private warrants (“Private Warrants”) that were converted into Rocket warrants with a right to purchase 617,050 of Rocket common shares at an exercise price of $65.23 per share. The Company determined that the Private Warrants did not meet all of the criteria for equity classification. Accordingly, the Company classifies the Private Warrants as derivative liabilities in its consolidated balance sheets. The Company measures the fair value of the warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company’s operating results for the current period. See Note 4 for discussion of fair value measurement of the warrant liabilities. Assumed Renovacor Pre-Funded Warrants In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-funded warrants (“Pre-Funded Warrants”) that were converted into Rocket warrants with a right to purchase 126,093 of Rocket common shares at an exercise price of $0.06 per share. These warrants were exercised in January 2023.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share [Abstract]
Net Loss Per Share	11. Net Loss Per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (65,701 ) $ (54,402 ) $ (124,036 ) $ (97,384 ) Denominator: Weighted-average common shares outstanding - basic and diluted 80,472,362 65,476,531 79,965,755 64,995,797 Net loss per share attributable to common stockholders $ (0.82 ) $ (0.83 ) $ (1.55 ) $ (1.50 ) The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three and Six Months Ended June 30, 2023 2022 Warrants exercisable for common shares 2,588,123 1,218,038 Restricted stock units convertible for common shares 1,654,759 527,304 Options to purchase common shares 14,875,150 12,526,751 19,118,032 14,272,093

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company’s consolidated balance sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company’s lease agreements contain renewal options; however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company’s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company’s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company’s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred. Finance Lease The Company has a lease for a facility in Cranbury, New Jersey, consisting of 103,720 square feet of space including areas for offices, process development, research, and development laboratories and 50,000 square feet dedicated to AAV Current Good Manufacturing Practice (“cGMP”) manufacturing facilities to support the Company’s pipeline (such lease, as amended, the “NJ Lease Agreement”). The NJ Lease Agreement has a 15-year term from September 1, 2019, with an option to renew for two consecutive five-year renewal terms. Estimated rent payments for the NJ Lease Agreement are $1.2 million per annum, payable in monthly installments, depending upon the nature of the leased space, and subject to annual base rent increases of 3%. The total commitment under the lease is estimated to be approximately $29.3 million over the 15-year term of the lease. The Company paid a cash security deposit of $0.3 million to the landlord in connection with the NJ Lease Agreement which has been reflected in deposits in the consolidated balance sheets as of June 30, 2023 and December 31, 2022. Operating Leases On June 7, 2018, the Company entered into a three-year lease agreement for office space in the Empire State Building in New York, NY (the “ESB Lease Agreement”). In connection with the ESB Lease Agreement, the Company established an irrevocable standby letter of credit (the “Empire LOC”) for $0.9 million. On March 26, 2021, the Company entered into Amendment No. 1 to the ESB Lease Agreement (“ESB Lease Amendment”) that extended the term of the lease agreement to June 30, 2024, reduced the rent payments going forward, and reduced the Empire LOC to $0.8 million. The Empire LOC serves as the Company’s security deposit on the lease in which the landlord is the beneficiary and expires August 29, 2024. The Company has a certificate of deposit of $0.8 million with a bank as collateral for the Empire LOC which is classified as part of restricted cash in the consolidated balance sheets as of June 30, 2023 and December 31, 2022. On January 4, 2018, in connection with the Reverse Merger with Inotek On November 15, 2022, the Company entered into a lease agreement with a lease term until October 31, 2024, for laboratory space in Madrid, Spain. The lease commenced on April 1, 2023 and the Company recognized a right-of-use asset and corresponding lease liability of approximately $0.2 million, respectively. On December 1, 2022, in connection with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), the Company acquired the Renovacor operating leases for space at facilities in Hopewell, New Jersey and Cambridge, Massachusetts with remaining lease terms of approximately 10.25 and 1.3 years, respectively. As of June 30, 2023, lease commencement dates have occurred for all leases and the Company recognized total right-of-use assets of $3.8 million with corresponding total lease liabilities of $3.6 million at lease commencement dates. The Company intends to sublease both premises through the remainder of their lease terms. Operating lease cost was $0.4 million and $0.7 million for the three and six months ended June 30, 2023, respectively. Operating lease cost was $0.2 million and $0.4 million for the for three and six months ended June 30, 2022, respectively. Rent expense was $0.5 million and $1.0 million for the three and six months ended June 30, 2023, respectively. Rent expense was $0.4 million and $0.7 million for the three and six months ended June 30, 2022, respectively. The total restricted cash balance for the Company’s operating and finance leases as of each of June 30, 2023 and December 31, 2022 was $0.8 million . Six Months Ended Lease cost June 30, 2023 Operating lease cost $ 742 Finance lease cost Amortization of right of use assets 1,077 Interest on lease liabilities 936 Total lease cost $ 2,755 The following table summarizes the future lease payments of the Company’s operating and finance lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and finance lease liabilities as of June 30, 2023: Fiscal Year Ending December 31, June 30, 2023 2023 (six months) 643 2024 903 2025 538 2026 545 2027 506 Thereafter 2,941 Total lease payments $ 6,076 Less: interest (1,769 ) Total operating lease liabilities $ 4,307 Fiscal Year Ending December 31, June 30, 2023 2023 (six months) 874 2024 1,791 2025 1,856 2026 1,912 2027 1,969 Thereafter 43,031 Total lease payments $ 51,433 Less: interest (30,354 ) Total finance lease liability $ 21,079 Leases June 30, 2023 Operating right-of-use assets $ 4,345 Operating current lease liabilities 1,233 Operating noncurrent lease liabilities 3,074 Total operating lease liabilities $ 4,307 Finance right-of-use assets $ 45,594 Finance current lease liability 1,760 Finance noncurrent lease liability 19,319 Total finance lease liability $ 21,079 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 582 Cash flows from finance lease $ 862 Weighted-average remaining lease term - operating leases 7.9 Weighted-average remaining lease term - finance lease 21.2 Weighted-average discount rate - operating leases 8.25 % Weighted-average discount rate - finance lease 8.96 % Litigation From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Indemnification Arrangements Pursuant to its bylaws and as permitted under Delaware law, the Company has indemnification obligations to directors, officers, employees or agents of the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal. Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company’s use of the vendor’s goods and/or services. The Company has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.

Agreements Related to Intellect

Agreements Related to Intellectual Property	6 Months Ended
	Jun. 30, 2023
Agreements Related to Intellectual Property [Abstract]
Agreements Related to Intellectual Property	13. Agreements Related to Intellectual Property The Company, directly and through its subsidiary Spacecraft Seven, LLC, has various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of rights to intellectual property which is in the preclinical phase and has not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols, or operating systems. The Company expenses the acquired intellectual property rights as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities has no alternative future uses.

Renovacor Acquisition

Renovacor Acquisition	6 Months Ended
	Jun. 30, 2023
Renovacor Acquisition [Abstract]
Renovacor Acquisition	14. Renovacor Acquisition On September 19, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Renovacor, a Delaware corporation pursuant to which, on December 1, 2022, the Company acquired Renovacor (the “Renovacor Acquisition”). On December 1, 2022, pursuant to the terms of the Merger Agreement, (i) Merger Sub I merged with and into the Company (the “First Merger”) and (ii) the Company, as the surviving company of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving the Second Merger. Subject to the terms and conditions of the Merger Agreement, at the closing of the Renovacor Acquisition each share of Renovacor’s common stock outstanding immediately prior to the effective time of the First Merger were canceled and converted into the right to receive 0.1763 (the “Exchange Ratio”) of fully paid and non-assessable shares of the Company common stock, which was determined on the basis of the exchange formula set forth in the Merger Agreement that was subject to adjustment depending on the level of the Renovacor’s net cash at the closing. Prior to the market opening on December 1, 2022, Renovacor shares ceased to trade on NYSE and upon the closing of the acquisition, Renovacor’s outstanding common stock were converted into 3,391,976 shares of Rocket common stock. Total consideration for the Renovacor Acquisition was $72.3 million, consisting of $62.4 million for common stock outstanding, $2.7 million for the portion of equity compensation attributable to the pre-combination service period, and $7.2 million for assumed warrants. The consideration was based on the estimated fair values on the acquisition date of (i) 3,391,976 common shares issued for shares outstanding for common shares of Renovacor, (ii) estimated fair value of employee stock options to acquire 367,852 common shares of the Company, (iii) 28,798 common shares issued for employee time-vesting RSUs, and (iv) warrants to acquire 1,503,229 common shares (see Note 10 “Warrants”). The total consideration for the acquisition of Renovacor of $72.3 million consisted of the following: Shares Value Total Stock consideration 3,391,976 $ 18.39 $ 62,378 Cash consideration (1) - 29 Stock options 367,852 2,163 Time-vesting RSUs 28,798 512 Assumed warrants (2) 1,503,229 7,183 Total consideration 5,291,855 $ 72,265 (1) Represents consideration paid for cash in lieu of fractional shares. (2) Assumed Renovacor Warrants of $7,183 with $5,671 classified as equity and $1,512 classified as liabilities. The acquisition has been accounted for as a business combination using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and that the fair value of acquired IPR&D assets are classified as indefinite-life assets until the successful completion or abandonment of the associated research and development efforts. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based on their respective preliminary fair values summarized below: Working capital (1) $ (5,210 ) Cash and cash equivalents 42,755 Property and equipment 1,414 Operating lease right-of-use assets 1,161 Other non-current assets 113 IPR&D 25,150 Other intangible asset 574 Operating lease liability (970 ) Deferred tax liability (1,061 ) Net assets acquired 63,926 Goodwill 8,339 Purchase consideration $ 72,265 (1) Includes other receivables, prepaid expenses, account payable and accrued liabilities. The fair value assigned to acquired IPR&D was based on the present value of expected after-tax cash flows attributable to Renovacor’s most advanced AAV-based gene therapy targeting BAG3-DCM. The present value of expected after-tax cash flows was determined by estimating the after-tax costs to complete development into a commercially viable product, estimating future revenue and ongoing expenses to produce, and discounting the resulting net cash flows to present value. The cost and revenue projections used were reduced based on the assessed probabilities of different stages of development. Acquired IPR&D will be accounted for as an indefinite-lived intangible asset until regulatory approval in a major market or discontinuation of development. The excess of purchase price over the fair value of amounts assigned to identifiable assets acquired and liabilities assumed represents the goodwill amount of $8.3 million resulting from the acquisition. The goodwill recorded as part of the acquisition is primarily attributable to the broadening of the Company’s portfolio and research capabilities, deferred taxes and the assembled workforce. The goodwill attributable to the acquisition has been recorded as a non-current asset in the Company’s consolidated balance sheet and is not amortized, but subject to review for impairment annually.

CIRM Grants

CIRM Grants	6 Months Ended
	Jun. 30, 2023
CIRM Grants [Abstract]
CIRM Grants	15. CIRM Grants LAD-1 CIRM Grant On April 30, 2019, the California Institute for Regenerative Medicine (“CIRM”) awarded the Company up to $7.5 million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy for RP-L201. Proceeds from the grant will help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles (“UCLA”) Mattel Children’s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Through June 30, 2023, the Company has received $5.9 million in total RP-L201 grants from CIRM. No additional milestones were achieved as of and for the six months ended June 30, 2023.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions In October 2020, the Company entered into a consulting agreement with the spouse of one of the Company’s executive officers for information technology advisory services. In exchange for the services provided under the agreement, the Company granted 10,000 restricted stock units which vest over a three-year period.

401(k) Savings Plan

401(k) Savings Plan	6 Months Ended
	Jun. 30, 2023
401(k) Savings Plan [Abstract]
401(k) Savings Plan	17. 401(k) Savings Plan The Company has a defined contribution savings plan (the “Plan”) under Section 401(k) of the Internal Revenue Code of 1986. This Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Company’s Board of Directors. The Company has elected the safe harbor match of 4% of employee contributions to the Plan, subject to certain limitations. The Company’s matching contribution for the three and six months ended June 30, 2023, was $0.3 million and $0.6 million, respectively. The Company’s matching contribution for the three and six months ended June 30, 2022, was $0.3 million and $0.5 million, respectively.

Basis of Presentation, Princi_2

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (“2022 Form 10-K”). The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s consolidated financial position as of June 30, 2023 and the results of its operations and its cash flows for the three and six months June 30, 2023. The financial data and other information disclosed in these consolidated notes related to the three and six months June 30, 2023 and 2022 are unaudited. The results for the three and six months ended June 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 and any other interim periods or any future year or period.
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies used in the preparation of these consolidated financial statements for the three and six months ended June 30, 2023 are consistent with those disclosed in Note 3 to the consolidated financial statements in the 2022 Form 10-K with most significant policies also being listed here.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany accounts have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of research and development (“R&D”) expenses, the valuation of equity transactions and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company’s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company’s operating leases (see Note 12 “Commitments and Contingencies” for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company’s corporate credit card. Cash, cash equivalents and restricted cash consist of the following: June 30, December 31, 2023 2022 Cash and cash equivalents $ 45,076 $ 140,517 Restricted cash 1,362 1,340 $ 46,438 $ 141,857
Concentrations of Credit Risk and Off-balance Sheet Risk	Concentrations of credit risk and off-balance sheet risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities consist of U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. The Company’s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.
Investments	Investments Investments consist of U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company’s consolidated statement of operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). For the three and six months ended June 30, 2023 and 2022, there were no unrealized losses that were credit related. For the three and six months ended June 30, 2023, there were net unrealized losses on investments of $0.6 million and $0.4 million, respectively. For the three and six months ended June 30, 2022 there were net unrealized losses on investments of $0.1 million and $0.6 million, respectively.
Intangible Assets	Intangible Assets Intangible assets related to in process research and development (“IPR&D”) projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&D intangible assets which are determined to have had a decrease in their fair value are adjusted downward and an expense is recognized in R&D expenses in the Consolidated Statements of Operations. These IPR&D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets.
Fair Value Measurements	Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company’s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.
Warrants	Warrants The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (”ASC 480”) and/or ASC Topic 815, Derivatives and Hedging (”ASC 815”), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company’s consolidated statement of operations.
Stock-Based Compensation	Stock-Based Compensation The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. That cost is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs and services are classified or in which the award recipient’s service payments are classified.
Income Taxes	Income Taxes In May 2022, the Company received a notice from the New York City Department of Finance regarding an audit of the NYC Biotechnology Credit for the tax periods ended December 31, 2018 through December 31, 2020, which was cleared as of June 30, 2023.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were no recent accounting pronouncements that impacted the Company, or which had a significant effect on the consolidated financial statements.

Basis of Presentation, Princi_3

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]
Cash, Cash Equivalents and Restricted Cash	Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company’s operating leases (see Note 12 “Commitments and Contingencies” for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company’s corporate credit card. Cash, cash equivalents and restricted cash consist of the following: June 30, December 31, 2023 2022 Cash and cash equivalents $ 45,076 $ 140,517 Restricted cash 1,362 1,340 $ 46,438 $ 141,857

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments Measured on Recurring Basis	Items measured at fair value on a recurring basis are the Company’s investments. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of June 30, 2023 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market mutual funds $ 17,173 $ - $ - $ 17,173 Corporate Bonds - 3,480 - 3,480 United States Treasury securities 3,620 - - 3,620 20,793 3,480 - 24,273 Investments: Commercial Paper - 5,002 - 5,002 United States Treasury securities 188,971 - - 188,971 Corporate Bonds - 58,040 - 58,040 Agency Bonds - 9,951 - 9,951 188,971 72,993 - 261,964 Total assets $ 209,764 $ 76,473 $ - $ 286,237 Liabilities: Warrant liability $ - $ - $ 1,012 $ 1,012 Total liabilities $ - $ - $ 1,012 $ 1,012 Fair Value Measurements as of December 31, 2022 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market mutual funds $ 90,527 $ - $ - $ 90,527 Commercial Paper - 3,899 - 3,899 United States Treasury Securities 3,848 - - 3,848 Corporate Bonds - 8,618 - 8,618 94,375 12,517 - 106,892 Investments: Commercial Paper - 1,151 - 1,151 United States Treasury securities 189,444 - - 189,444 Corporate Bonds - 60,905 - 60,905 Agency Bonds - 7,653 - 7,653 189,444 69,709 - 259,153 Total assets $ 283,819 $ 82,226 $ - $ 366,045 Liabilities: Warrant liability $ - $ - $ 1,512 $ 1,512 Total liabilities $ - $ - $ 1,512 $ 1,512
Changes in Level 3 Liabilities Measured at Fair Value	The reconciliation of the Company’s warrant liability, which is recorded as part of Other Liabilities in the consolidated balance sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrant Liability Balance, December 31, 2022 $ 1,512 Fair value adjustments (500 ) Balance, June 30, 2023 $ 1,012
Level 3 Fair Value of the Private Warrants	The fair value of the warrant liability has been estimated with the following assumptions: June 30, 2023 December 31, 2022 Stock price $ 19.87 $ 18.39 Exercise price $ 65.23 $ 65.23 Expected volatility 67.91 % 71.25 % Risk-free interest rate 4.97 % 4.14 % Expected dividend yield - - Expected life (years) 1.82 2.39 Fair value per warrant $ 1.64 $ 2.45

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property and Equipment, Net [Abstract]
Property and Equipment	The Company’s property and equipment consisted of the following: June 30, December 31, 2023 2022 Laboratory equipment $ 24,723 $ 21,905 Machinery and equipment 11,714 11,326 Computer equipment 244 244 Furniture and fixtures 2,535 2,135 Leasehold improvements 3,289 589 Internal use software 1,903 1,903 44,408 38,102 Less: accumulated depreciation and amortization (11,422 ) (9,093 ) $ 32,986 $ 29,009

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2023
Intangible Assets and Goodwill [Abstract]
Summary of Intangible Assets	Intangible assets as of June 30, 2023 and December 31, 2022 are summarized as follows: Gross Carrying Value Accumulated Amortization Intangible Assets, Net In process research & development $ 25,150 $ - $ 25,150 Mice colony model 574 - 574 Total intangible assets $ 25,724 $ - $ 25,724

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	As of June 30, 2023 and December 31, 2022, the Company’s accounts payable and accrued expenses consisted of the following: June 30 , December 31, 2023 2022 Research and development $ 20,329 $ 19,100 Employee compensation 6,013 10,006 Property and equipment 1,265 2,095 Professional fees 2,034 1,436 Acquisition related expenses - 1,153 Government grant payable 597 597 Other 1,115 2,273 $ 31,353 $ 36,660

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Stock-Based Compensation [Abstract]
Weighted-Average Assumptions for Stock Options	The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of stock options granted to employees, non-employees and directors were as follows: Six June 30 2023 2022 Risk-free interest rate 3.96 % 2.32 % Expected term (in years) 5.84 5.79 Expected volatility 73.42 % 73.26 % Expected dividend yield - - Exercise price $ 20.20 $ 15.93 Fair value of common stock $ 20.20 $ 15.93
Stock Option Activity	The following table summarizes stock option activity for the six months ended June 30, 2023: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding as of December 31, 2022 13,138,870 $ 14.52 5.46 $ 118,767 Granted 2,142,111 20.36 6.73 Exercised (136,517 ) 9.50 1,334 Cancelled or forfeited (269,314 ) 32.45 Outstanding as of June 30 2023 14,875,150 $ 15.08 5.67 $ 120,465 Options vested and exercisable as of June 30 2023 11,205,612 $ 12.91 4.51 $ 116,486 Options unvested as of June 30 2023 3,669,538 $ 21.71 9.23 $ 3,979
RSU Activity	The following table summarizes the Company’s RSU activity for the six months ended June 30, 2023: Weighted Average Number of Grant Date Shares Fair Value Unvested as of December 31, 2022 992,874 $ 16.49 Granted 887,637 19.91 Vested (1) (187,297 ) 16.63 Forfeited (38,455 ) 18.33 Unvested as of June 30, 2023 1,654,759 $ 18.27 (1) Common stock issued is net of 104 shares related to taxes.
Stock-Based Compensation Expense by Award Type	Stock-based compensation expense recognized by award type was as follows: Three Months Ended June 30, Six June 30 2023 2022 2023 2022 Stock options $ 7,455 $ 6,677 $ 14,440 $ 12,638 Restricted stock units 2,790 692 4,720 1,001 Total stock-based compensation expense $ 10,245 $ 7,369 $ 19,160 $ 13,639
Stock-Based Compensation Expense	Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 4,638 $ 2,889 $ 8,457 $ 5,207 General and administrative 5,607 4,480 10,703 8,432 Total stock-based compensation expense $ 10,245 $ 7,369 $ 19,160 $ 13,639

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2023
Warrants [Abstract]
Warrants Outstanding and Changes in Warrants to Purchase Common Stock	A summary of the warrants outstanding as of June 30, 2023 is as follows: Exercise Price Outstanding Grant/Assumption Date Expiration Date 57.11 603,386 December 21, 2020 December 21, 2030 33.63 301,291 August 9, 2021 August 9, 2031 22.51 153,155 December 17, 2021 December 17, 2031 22.51 153,155 December 17, 2021 December 17, 2031 65.23 617,050 December 1, 2022 April 23, 2025 65.23 760,086 December 1, 2022 December 1, 2026 Total 2,588,123 The following table below is a summary of changes in warrants to purchase common stock for the six months ended June 30, 2023: Number of Warrant Shares Outstanding and Exercise Price Exercisable per Share Balance as of December 31, 2022 2,721,267 Granted - $ - Exercised (126,093 ) 0.06 Expired (7,051 ) $ 24.42 Balance as of June 30, 2023 2,588,123

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share [Abstract]
Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (65,701 ) $ (54,402 ) $ (124,036 ) $ (97,384 ) Denominator: Weighted-average common shares outstanding - basic and diluted 80,472,362 65,476,531 79,965,755 64,995,797 Net loss per share attributable to common stockholders $ (0.82 ) $ (0.83 ) $ (1.55 ) $ (1.50 )
Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three and Six Months Ended June 30, 2023 2022 Warrants exercisable for common shares 2,588,123 1,218,038 Restricted stock units convertible for common shares 1,654,759 527,304 Options to purchase common shares 14,875,150 12,526,751 19,118,032 14,272,093

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Lease Cost	Six Months Ended Lease cost June 30, 2023 Operating lease cost $ 742 Finance lease cost Amortization of right of use assets 1,077 Interest on lease liabilities 936 Total lease cost $ 2,755
Future Lease Payments of Operating Lease Liabilities	The following table summarizes the future lease payments of the Company’s operating and finance lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and finance lease liabilities as of June 30, 2023: Fiscal Year Ending December 31, June 30, 2023 2023 (six months) 643 2024 903 2025 538 2026 545 2027 506 Thereafter 2,941 Total lease payments $ 6,076 Less: interest (1,769 ) Total operating lease liabilities $ 4,307
Future Lease Payments of Finance Lease Liability	Fiscal Year Ending December 31, June 30, 2023 2023 (six months) 874 2024 1,791 2025 1,856 2026 1,912 2027 1,969 Thereafter 43,031 Total lease payments $ 51,433 Less: interest (30,354 ) Total finance lease liability $ 21,079
Balance Sheet Information Related to Leases	Leases June 30, 2023 Operating right-of-use assets $ 4,345 Operating current lease liabilities 1,233 Operating noncurrent lease liabilities 3,074 Total operating lease liabilities $ 4,307 Finance right-of-use assets $ 45,594 Finance current lease liability 1,760 Finance noncurrent lease liability 19,319 Total finance lease liability $ 21,079
Lease Related to Cash Flow Information, Lease Term and Discount Rate	Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 582 Cash flows from finance lease $ 862 Weighted-average remaining lease term - operating leases 7.9 Weighted-average remaining lease term - finance lease 21.2 Weighted-average discount rate - operating leases 8.25 % Weighted-average discount rate - finance lease 8.96 %

Renovacor Acquisition (Tables)

Renovacor Acquisition (Tables)	6 Months Ended
	Jun. 30, 2023
Renovacor Acquisition [Abstract]
Total Consideration for Acquisition	The total consideration for the acquisition of Renovacor of $72.3 million consisted of the following: Shares Value Total Stock consideration 3,391,976 $ 18.39 $ 62,378 Cash consideration (1) - 29 Stock options 367,852 2,163 Time-vesting RSUs 28,798 512 Assumed warrants (2) 1,503,229 7,183 Total consideration 5,291,855 $ 72,265 (1) Represents consideration paid for cash in lieu of fractional shares. (2) Assumed Renovacor Warrants of $7,183 with $5,671 classified as equity and $1,512 classified as liabilities.
Purchase Price allocation of Assets Acquired and Liabilities Assumed	The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based on their respective preliminary fair values summarized below: Working capital (1) $ (5,210 ) Cash and cash equivalents 42,755 Property and equipment 1,414 Operating lease right-of-use assets 1,161 Other non-current assets 113 IPR&D 25,150 Other intangible asset 574 Operating lease liability (970 ) Deferred tax liability (1,061 ) Net assets acquired 63,926 Goodwill 8,339 Purchase consideration $ 72,265 (1) Includes other receivables, prepaid expenses, account payable and accrued liabilities.

Nature of Business (Details)

Nature of Business (Details)	6 Months Ended
	Jun. 30, 2023 Program
Nature of Business [Abstract]
Number of clinical-stage programs	3

Risks and Liquidity (Details)

Risks and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 28, 2022
Risks and Liquidity [Abstract]
Accumulated deficit	$ (837,811)		$ (713,775)
Cash, cash equivalents and investments	$ 307,000
Shareholders' Equity Disclosure [Abstract]
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01
Issuance of common stock, net of issuance costs	$ 17,222	$ 17,243
At-the-Market Offering [Member]
Shareholders' Equity Disclosure [Abstract]
Common stock shares issued and sold (in shares)	0.9
Issuance of common stock, net of issuance costs	$ 17,200
At-the-Market Offering [Member] | Cowen and Company, LLC [Member]
Shareholders' Equity Disclosure [Abstract]
Common stock, par value (in dollars per share)				$ 0.01
Common stock shares issued and sold (in shares)	4.2
Issuance of common stock, net of issuance costs	$ 63,800
At-the-Market Offering [Member] | Cowen and Company, LLC [Member] | Maximum [Member]
Shareholders' Equity Disclosure [Abstract]
Aggregate offering price				$ 200,000

Basis of Presentation, Princi_4

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies, Summary (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Cash, Cash Equivalents and Restricted Cash [Abstract]
Cash and cash equivalents	$ 45,076	$ 140,517
Restricted cash	1,362	1,340
Total	$ 46,438	$ 141,857	$ 188,891	$ 234,037

Basis of Presentation, Princi_5

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies, Investments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Investments [Abstract]
Net unrealized loss on credit investments	$ 0	$ 0	$ 0	$ 0
Net unrealized loss on investments	$ (600)	$ (100)	$ (365)	$ (604)

Fair Value of Financial Instr_3

Fair Value of Financial Instruments, Measured on Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets [Abstract]
Cash equivalents	$ 24,273	$ 106,892
Investments	261,964	259,153
Fair value of financial instruments	286,237	366,045
Liabilities [Abstract]
Total liabilities	1,012	1,512
Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	1,012	1,512
Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	17,173	90,527
Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		3,899
Investments	5,002	1,151
United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	3,620	3,848
Investments	188,971	189,444
Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	3,480	8,618
Investments	58,040	60,905
Agency Bonds [Member]
Assets [Abstract]
Investments	9,951	7,653
Level 1 [Member]
Assets [Abstract]
Cash equivalents	20,793	94,375
Investments	188,971	189,444
Fair value of financial instruments	209,764	283,819
Liabilities [Abstract]
Total liabilities	0	0
Level 1 [Member] | Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	0	0
Level 1 [Member] | Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	17,173	90,527
Level 1 [Member] | Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		0
Investments	0	0
Level 1 [Member] | United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	3,620	3,848
Investments	188,971	189,444
Level 1 [Member] | Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 1 [Member] | Agency Bonds [Member]
Assets [Abstract]
Investments	0	0
Level 2 [Member]
Assets [Abstract]
Cash equivalents	3,480	12,517
Investments	72,993	69,709
Fair value of financial instruments	76,473	82,226
Liabilities [Abstract]
Total liabilities	0	0
Level 2 [Member] | Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	0	0
Level 2 [Member] | Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	0	0
Level 2 [Member] | Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		3,899
Investments	5,002	1,151
Level 2 [Member] | United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 2 [Member] | Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	3,480	8,618
Investments	58,040	60,905
Level 2 [Member] | Agency Bonds [Member]
Assets [Abstract]
Investments	9,951	7,653
Level 3 [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Fair value of financial instruments	0	0
Liabilities [Abstract]
Total liabilities	1,012	1,512
Level 3 [Member] | Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	1,012	1,512
Level 3 [Member] | Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	0	0
Level 3 [Member] | Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		0
Investments	0	0
Level 3 [Member] | United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 3 [Member] | Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 3 [Member] | Agency Bonds [Member]
Assets [Abstract]
Investments	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments, Changes in Level 3 Liabilities Measured at Fair Value (Details) - Recurring [Member] - Level 3 [Member] - Warrant Liability [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Changes in Fair Value of Warrant Liabilities [Roll Forward]
Fair value, beginning of period	$ 1,512
Fair value adjustments	(500)
Fair value, end of period	$ 1,012

Fair Value of Financial Instr_5

Fair Value of Financial Instruments, Level 3 Fair Value of the Private Warrants (Details) - Private Warrants [Member]	Jun. 30, 2023 $ / shares	Dec. 31, 2022 $ / shares
Fair Value of the Private Warrants, Assumptions [Abstract]
Term	1 year 9 months 25 days	2 years 4 months 20 days
Fair value per warrant (in dollars per share)	$ 1.64	$ 2.45
Stock Price [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	19.87	18.39
Exercise Price [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	65.23	65.23
Expected Volatility [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0.6791	0.7125
Risk-Free Interest Rate [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0.0497	0.0414
Expected Dividend Yield [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0	0

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property and Equipment [Abstract]
Property and equipment, gross	$ 44,408		$ 44,408		$ 38,102
Less: accumulated depreciation and amortization	(11,422)		(11,422)		(9,093)
Property and equipment, net	32,986		32,986		29,009
Depreciation and amortization	1,200	$ 1,000	2,327	$ 1,798
Laboratory Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	24,723		24,723		21,905
Machinery and Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	11,714		11,714		11,326
Computer Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	244		244		244
Furniture and Fixtures [Member]
Property and Equipment [Abstract]
Property and equipment, gross	2,535		2,535		2,135
Leasehold Improvements [Member]
Property and Equipment [Abstract]
Property and equipment, gross	3,289		3,289		589
Internal use Software [Member]
Property and Equipment [Abstract]
Property and equipment, gross	$ 1,903		$ 1,903		$ 1,903

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 01, 2022
Intangible Assets, Net [Abstract]
Gross Carrying Value	$ 25,724
Intangible Assets, Net	25,724	$ 25,724
Goodwill	39,154	$ 39,154
Renovacor, Inc. [Member]
Intangible Assets, Net [Abstract]
Goodwill	8,300		$ 8,339
In Process Research & Development [Member]
Intangible Assets, Net [Abstract]
Gross Carrying Value	25,150
Intangible Assets, Net	25,150
Mice Colony Model [Member]
Intangible Assets, Net [Abstract]
Gross Carrying Value	574
Intangible Assets, Net	$ 574

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts Payable and Accrued Expenses [Abstract]
Research and development	$ 20,329	$ 19,100
Employee compensation	6,013	10,006
Property and equipment	1,265	2,095
Professional fees	2,034	1,436
Acquisition related expenses	0	1,153
Government grant payable	597	597
Other	1,115	2,273
Accounts payable and accrued expenses	$ 31,353	$ 36,660

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ in Thousands, shares in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Feb. 28, 2022
At-the-Market Offering Program [Abstract]
Net proceeds from offering	$ 17,222	$ 17,243
At-the-Market Offering Program [Member]
At-the-Market Offering Program [Abstract]
Issuance of common stock, net of issuance costs (in shares)	0.9
Gross proceeds, offering amount	$ 17,800
Commissions	600
Net proceeds from offering	$ 17,200
At-the-Market Offering Program [Member] | Cowen and Company, LLC [Member]
At-the-Market Offering Program [Abstract]
Percentage of cash commission			3%
Issuance of common stock, net of issuance costs (in shares)	4.2
Gross proceeds, offering amount	$ 65,800
Commissions	2,000
Net proceeds from offering	$ 63,800

Stock-Based Compensation, Share

Stock-Based Compensation, Share Option Valuation (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Stock Option Activity [Roll Forward]
Outstanding at beginning of period (in shares)	13,138,870
Granted (in shares)	2,142,111
Exercised (in shares)	(136,517)
Cancelled or forfeited (in shares)	(269,314)
Outstanding at end of period (in shares)	14,875,150		13,138,870
Options vested and exercisable at end of period (in shares)	11,205,612
Options unvested at ending of period (in shares)	3,669,538
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 14.52
Granted (in dollars per share)	20.36
Exercised (in dollars per share)	9.5
Cancelled or forfeited (in dollars per share)	32.45
Outstanding at end of period (in dollars per share)	15.08		$ 14.52
Options vested and exercisable at end of period (in dollars per share)	12.91
Options unvested at ending (in dollars per share)	$ 21.71
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	5 years 8 months 1 day		5 years 5 months 15 days
Granted	6 years 8 months 23 days
Options vested and exercisable	4 years 6 months 3 days
Options unvested	9 years 2 months 23 days
Aggregate Intrinsic Value [Abstract]
Outstanding at beginning of period	$ 118,767
Exercised	1,334
Outstanding at end of period	120,465		$ 118,767
Options vested and exercisable	116,486
Options unvested	$ 3,979
Weighted average grant date fair value of shares granted (in dollars per share)	$ 13.46	$ 10.32
Total fair value of options vested	$ 19,900	$ 20,800
Employees, Non-employees and Directors [Member]
Weighted-Average Assumptions [Abstract]
Risk-free interest rate	3.96%	2.32%
Expected term	5 years 10 months 2 days	5 years 9 months 14 days
Expected volatility	73.42%	73.26%
Expected dividend yield	0%	0%
Exercise price (in dollars per share)	$ 20.2	$ 15.93
Fair value of common stock (in dollars per share)	$ 20.2	$ 15.93

Stock-Based Compensation, Restr

Stock-Based Compensation, Restricted Stock Units (Details) - Restricted Stock Units (RSU) [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Shares [Roll Forward]
Beginning balance (in shares)	992,874
Granted (in shares)	887,637
Vested (in shares)	(187,297)	[1]
Forfeited (in shares)	(38,455)
Ending balance (in shares)	1,654,759
Weighted Average Grant Date Fair Value [Abstract]
Beginning balance (in dollars per share) | $ / shares	$ 16.49
Granted (in dollars per share) | $ / shares	19.91
Vested (in dollars per share) | $ / shares	16.63	[1]
Forfeited (in dollars per share) | $ / shares	18.33
Ending balance (in dollars per share) | $ / shares	$ 18.27
Common stock shares issued related to tax (in shares)	104
[1] Common stock issued is net of 104 shares related to taxes.

Stock-Based Compensation, Stock

Stock-Based Compensation, Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	$ 10,245	$ 7,369	$ 19,160	$ 13,639
Research and Development [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	4,638	2,889	8,457	5,207
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	5,607	4,480	10,703	8,432
Stock Options [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	7,455	6,677	14,440	12,638
Unrecognized stock-based compensation expense	70,500		$ 70,500
Weighted average period expected to recognize unrecognized stock-based compensation expense			1 year 5 months 12 days
Restricted Stock Units [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	2,790	$ 692	$ 4,720	$ 1,001
Unrecognized stock-based compensation expense	$ 70,500		$ 70,500
Weighted average period expected to recognize unrecognized stock-based compensation expense			1 year 5 months 12 days

Warrants, Rocket Warrants (Deta

Warrants, Rocket Warrants (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Warrants [Member]
Warrants [Abstract]
Outstanding (in shares)	2,588,123
Number of Warrant Shares Outstanding and Exercisable [Abstract]
Beginning balance (in shares)	2,721,267
Granted (in shares)	0
Exercised (in shares)	(126,093)
Expired (in shares)	(7,051)
Ending balance (in shares)	2,588,123
Exercise Price Per Share [Abstract]
Granted (in dollars per share) | $ / shares	$ 0
Exercised (in dollars per share) | $ / shares	0.06
Expired (in dollars per share) | $ / shares	24.42
57.11 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 57.11
Outstanding (in shares)	603,386
Grant date	Dec. 21, 2020
Expiration date	Dec. 21, 2030
33.63 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 33.63
Outstanding (in shares)	301,291
Grant date	Aug. 09, 2021
Expiration date	Aug. 09, 2031
22.51 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 22.51
Outstanding (in shares)	153,155
Grant date	Dec. 17, 2021
Expiration date	Dec. 17, 2031
22.51 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 22.51
Outstanding (in shares)	153,155
Grant date	Dec. 17, 2021
Expiration date	Dec. 17, 2031
65.23 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 65.23
Outstanding (in shares)	617,050
Grant date	Dec. 01, 2022
Expiration date	Apr. 23, 2025
65.23 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) | $ / shares	$ 65.23
Outstanding (in shares)	760,086
Grant date	Dec. 01, 2022
Expiration date	Dec. 01, 2026

Warrants, Renovacor Warrants (D

Warrants, Renovacor Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Warrants [Abstract]
Additional paid-in capital	$ 1,240,745	$ 1,203,074
Public Warrants [Member]
Warrants [Abstract]
Additional paid-in capital	$ 3,400
Public Warrants [Member] | Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	760,086
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 65.23
Private Warrants [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 1.64	$ 2.45
Private Warrants [Member] | Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	617,050
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 65.23
Pre-Funded Warrants [Member] | Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	126,093
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 0.06

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator [Abstract]
Net loss attributable to common stockholders	$ (65,701)	$ (54,402)	$ (124,036)	$ (97,384)
Denominator [Abstract]
Weighted-average common shares outstanding - basic (in shares)	80,472,362	65,476,531	79,965,755	64,995,797
Weighted-average common shares outstanding - diluted (in shares)	80,472,362	65,476,531	79,965,755	64,995,797
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.82)	$ (0.83)	$ (1.55)	$ (1.5)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.82)	$ (0.83)	$ (1.55)	$ (1.5)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Warrants exercisable for common shares (in shares)	2,588,123	1,218,038	2,588,123	1,218,038
Restricted stock units convertible for common shares (in shares)	1,654,759	527,304	1,654,759	527,304
Options to purchase common shares (in shares)	14,875,150	12,526,751	14,875,150	12,526,751
Weighted average number diluted shares outstanding (in shares)	19,118,032	14,272,093	19,118,032	14,272,093

Commitments and Contingencies,

Commitments and Contingencies, Finance Lease (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) ft² LeaseAgreement	Dec. 31, 2022 USD ($)
Finance Lease [Abstract]
Total lease payments	$ 51,433
Cash security deposit	$ 542	$ 608
NJ Lease Agreement [Member]
Finance Lease [Abstract]
Area of lease | ft²	103,720
Term of finance lease agreement	15 years
Number of options to renew lease agreement | LeaseAgreement	2
Term of renewal of finance lease agreement	5 years
Estimated rent payments	$ 1,200
Percentage of annual increase in base rent	3%
Total lease payments	$ 29,300
Cash security deposit	$ 300	$ 300
AAV Current Good Manufacturing Practice (cGMP) [Member]
Finance Lease [Abstract]
Area of lease | ft²	50,000

Commitments and Contingencies_2

Commitments and Contingencies, Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Dec. 31, 2022	Jun. 07, 2018
Operating Leases [Abstract]
Lease expiration date			Oct. 31, 2024
Total right-of-use asset	$ 4,345		$ 4,345		$ 200	$ 1,972
Total lease liabilities	3,074		3,074		$ 200	1,088
Operating lease cost	400	$ 200	742	$ 400
Rent expense	500	400	1,000	700
Restricted cash	1,362		1,362			1,340
Operating and Finance Leases [Member]
Operating Leases [Abstract]
Restricted cash	800		800			800
Renovacor, Inc. [Member]
Operating Leases [Abstract]
Total right-of-use asset	3,800		3,800
Total lease liabilities	$ 3,600		$ 3,600
ESB Lease Agreement [Member]
Operating Leases [Abstract]
Term of lease agreement	3 years		3 years
Letter of credit							$ 900
Lease expiration date			Aug. 29, 2024
Certificate of deposit	$ 800		$ 800			$ 800
ESB Lease Agreement Amendment [Member]
Operating Leases [Abstract]
Letter of credit	800		$ 800
Lease expiration date			Jun. 30, 2024
Inotek Lexington Massachusetts Lease Agreement [Member]
Operating Leases [Abstract]
Lease expiration date			Feb. 28, 2023
Rental income received under sublease agreements	$ 100	$ 200	$ 100	$ 200
Remaining lease term	1 year 3 months 18 days		1 year 3 months 18 days
Inotek Lexington Massachusetts Lease Agreement [Member] | Hopewell, New Jersey and Cambridge [Member]
Operating Leases [Abstract]
Remaining lease term	10 years 3 months		10 years 3 months
Other Current Assets [Member]
Operating Leases [Abstract]
Security deposit	$ 200		$ 200

Commitments and Contingencies_3

Commitments and Contingencies, Details of Operating and Finance Lease (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Lease cost [Abstract]
Operating lease cost	$ 400	$ 200	$ 742	$ 400
Finance lease cost [Abstract]
Amortization of right of use assets			1,077
Interest on lease liabilities			936
Total lease cost			2,755
Future Lease Payments of Operating Lease Liabilities [Abstract]
2023 (six months)	643		643
2024	903		903
2025	538		538
2026	545		545
2027	506		506
Thereafter	2,941		2,941
Total lease payments	6,076		6,076
Less: interest	(1,769)		(1,769)
Total operating lease liabilities	4,307		4,307
Future Lease Payments of Finance Lease Liability [Abstract]
2023 (six months)	874		874
2024	1,791		1,791
2025	1,856		1,856
2026	1,912		1,912
2027	1,969		1,969
Thereafter	43,031		43,031
Total lease payments	51,433		51,433
Less: interest	(30,354)		(30,354)
Total finance lease liability	21,079		21,079
Lease assets and liabilities [Abstract]
Operating right-of-use assets	4,345		4,345		$ 200	$ 1,972
Operating current lease liabilities	1,233		1,233			773
Operating noncurrent lease liabilities	3,074		3,074		$ 200	1,088
Total operating lease liabilities	4,307		4,307
Finance right-of-use assets	45,594		45,594			46,664
Finance current lease liability	1,760		1,760			1,736
Finance noncurrent lease liability	19,319		19,319			$ 19,269
Total finance lease liability	$ 21,079		21,079
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows from operating leases			582
Cash flows from finance lease			$ 862
Weighted-average remaining lease term - operating leases	7 years 10 months 24 days		7 years 10 months 24 days
Weighted-average remaining lease term - finance lease	21 years 2 months 12 days		21 years 2 months 12 days
Weighted-average discount rate - operating leases	8.25%		8.25%
Weighted-average discount rate - finance lease	8.96%		8.96%

Renovacor Acquisition (Details)

Renovacor Acquisition (Details) $ / shares in Units, $ in Thousands		Dec. 01, 2022 USD ($) $ / shares shares	Sep. 19, 2022	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]
Goodwill				$ 39,154	$ 39,154
Renovacor, Inc. [Member]
Business Combination [Abstract]
Exchange ratio			0.1763
Business Combination, Consideration Transferred [Abstract]
Stock consideration (in shares) | shares		5,291,855
Cash consideration	[1]	$ 29
Equity consideration, value		2,700
Total consideration		72,265
Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]
Working capital	[2]	(5,210)
Cash and cash equivalents		42,755
Property and equipment		1,414
Operating lease right-of-use assets		1,161
Other non-current assets		113
IPR&D		25,150
Other intangible asset		574
Operating lease liability		(970)
Deferred tax liability		(1,061)
Net assets acquired		63,926
Goodwill		8,339		$ 8,300
Purchase consideration		$ 72,265
Renovacor, Inc. [Member] | Assumed Warrants [Member]
Business Combination, Consideration Transferred [Abstract]
Stock consideration (in shares) | shares	[3]	1,503,229
Equity consideration, value	[3]	$ 7,183
Renovacor, Inc. [Member] | Warrants, Classified as Equity [Member]
Business Combination, Consideration Transferred [Abstract]
Equity consideration, value		5,671
Renovacor, Inc. [Member] | Warrants Classified as Liabilities [Member]
Business Combination, Consideration Transferred [Abstract]
Equity consideration, value		$ 1,512
Renovacor, Inc. [Member] | Stock Options [Member]
Business Combination, Consideration Transferred [Abstract]
Stock consideration (in shares) | shares		367,852
Equity consideration, value		$ 2,163
Renovacor, Inc. [Member] | Time Vesting RSU [Member]
Business Combination, Consideration Transferred [Abstract]
Stock consideration (in shares) | shares		28,798
Equity consideration, value		$ 512
Renovacor, Inc. [Member] | Stock Consideration [Member]
Business Combination, Consideration Transferred [Abstract]
Stock consideration (in shares) | shares		3,391,976
Share price (in dollars per share) | $ / shares		$ 18.39
Equity consideration, value		$ 62,378
[1]Represents consideration paid for cash in lieu of fractional shares.[2] Includes other receivables, prepaid expenses, account payable and accrued liabilities.

CIRM Grants (Details)

CIRM Grants (Details) - LAD-1 CIRM Grant [Member] $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) Milestone	Apr. 30, 2019 USD ($)
CIRM Grants [Abstract]
Grant award for clinical development support		$ 7.5
Milestone payments received	$ 5.9
Number of milestones achieved | Milestone	0

Related Party Transactions (Det

Related Party Transactions (Details) - Restricted Stock Units (RSU) [Member] - shares	1 Months Ended	6 Months Ended
	Oct. 31, 2020	Jun. 30, 2023
Related Party Transaction [Abstract]
Shares granted (in shares)		887,637
Spouse of Executive officer [Member]
Related Party Transaction [Abstract]
Shares granted (in shares)	10,000
Vesting period		3 years

401(k) Savings Plan (Details)

401(k) Savings Plan (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
401(k) Savings Plan [Abstract]
Percentage of matching employee contributions			4%
Matching employee contributions	$ 0.3	$ 0.3	$ 0.6	$ 0.5